S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.
about
Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer TherapyS100A7 promotes the migration, invasion and metastasis of human cervical cancer cells through epithelial-mesenchymal transitionDifferential Gene Expression Landscape of Co-Existing Cervical Pre-Cancer Lesions Using RNA-seqTGFβ loss activates ADAMTS-1-mediated EGF-dependent invasion in a model of esophageal cell invasion.Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study.The Characteristics and Function of S100A7 Induction in Squamous Cell Carcinoma: Heterogeneity, Promotion of Cell Proliferation and Suppression of DifferentiationAnticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.Nucleus Accumbens-Associated Protein 1 Expression Has Potential as a Marker for Distinguishing Oral Epithelial Dysplasia and Squamous Cell CarcinomaPrediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancerOpposing Effects of Zac1 and Curcumin on AP-1-Regulated Expressions of S100A7Establishment of a new OSCC cell line derived from OLK and identification of malignant transformation-related proteins by differential proteomics approach.Targeting of chemoprevention to high-risk potentially malignant oral lesions: challenges and opportunities.Nuclear heterogeneous nuclear ribonucleoprotein D is associated with poor prognosis and interactome analysis reveals its novel binding partners in oral cancer.Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosisER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.DNA damage marker phosphorylated histone H2AX is a potential predictive marker for progression of epithelial dysplasia of the oral cavity.Chronic periodontitis can affect the levels of potential oral cancer salivary mRNA biomarkers.
P2860
Q28546757-338C420F-F952-4DFD-9094-785FF60C88C2Q33648719-EC47890B-6B42-4073-9CA6-6145F784BFA0Q34574451-E213F1FB-6CEC-4099-BB6D-C16278D336D2Q34713738-FB8EFC3E-116B-4B93-9B99-18ACB614DD6DQ35072838-153A00F8-B82C-4742-AE61-705F353DB509Q35580127-01902164-2558-4367-9878-98234F22FECCQ35656741-A716E246-100B-4885-B170-160859497FD1Q35675984-8ECA6554-57EA-4FE1-A024-B699CB3DA802Q35690714-CF3CBD2A-1478-4811-89ED-366CDBF532B1Q35818215-F9E62E7F-B460-492D-9944-CDF47C77504DQ35860140-12AC75A6-0DB9-4FF7-B4D7-9B915C28A364Q35909735-27E3CA48-04D1-4D0E-9846-303072B5EBBFQ35963741-E1633129-D3B2-406F-8451-85F04D880BC3Q36006304-52F0320C-72FB-470D-95BE-4A8A384C1F25Q36078946-5C5BDF55-1705-4D37-9028-FEDB2A7A419BQ37086229-29420088-053D-44DB-AF5B-3F93670008EDQ38376361-4ABAF4EA-04AD-4BFF-BF1E-D5E6E565B976Q51557293-FD54BB33-FE01-4891-9759-A152FD48F785
P2860
S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
S100A7 overexpression is a pre ...... nsformation in oral dysplasia.
@en
S100A7 overexpression is a pre ...... nsformation in oral dysplasia.
@nl
type
label
S100A7 overexpression is a pre ...... nsformation in oral dysplasia.
@en
S100A7 overexpression is a pre ...... nsformation in oral dysplasia.
@nl
prefLabel
S100A7 overexpression is a pre ...... nsformation in oral dysplasia.
@en
S100A7 overexpression is a pre ...... nsformation in oral dysplasia.
@nl
P2093
P2860
P356
P1476
S100A7 overexpression is a pre ...... nsformation in oral dysplasia.
@en
P2093
Ajay Matta
Christina Macmillan
Gunjan Srivastava
Ian Witterick
Iona Leong
Ipshita Kak
Jasmeet Assi
K W Michael Siu
Paul G Walfish
Ranju Ralhan
P2860
P304
P356
10.1002/IJC.28473
P577
2013-10-08T00:00:00Z